Aldeyra Therapeutics Inc. Common Stock (ALDX)
Stock · NASDAQ · Health Care
$1.49as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$1.56
Industry
Biotechnology: Pharmaceutical Preparations
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lympho…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- www.aldeyra.com/
Fundamentals
- 1-day range
- $1.48$1.56
- Market cap
- $92.29M
- P/E (trailing)
- —
- P/E (forward)
- -5.40
- EPS (trailing)
- $-0.38
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 1.33M
52-week range
$1.07$6.18
Next earnings: November 4, 2026 · EPS estimate $-0.09confirmed
Forecasts
5 analyst ratings
Buy 83%
Hold 17%
Sell 0%
1-year price forecast
High
$13
+775.4%
Median
$5
+236.7%
Low
$2
+34.7%
Aldeyra Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALDXAldeyra Therapeutics Inc. Common Stock$1.49▼ 3.57%Market cap $92.29MP/E —$1.07$6.18
- ONCYOncolytics Biotech Inc. Common Stock$0.8457▼ 0.51%Market cap $92.50MP/E —$1.39$1.44
- FBIOFortress Biotech Inc. Common Stock$2.77▼ 1.07%Market cap $91.68MP/E 0.75$2.18$4.53
- VRCAVerrica Pharmaceuticals Inc. Common Stock$5.54▲ 9.27%Market cap $90.19MP/E —$3.28$9.82
- NTHINeOnc Technologies Holdings Inc. Common Stock$4.69▲ 1.74%Market cap $89.73MP/E —$3.01$12.99
- ACETAdicet Bio Inc. Common Stock$9.05▲ 0.44%Market cap $86.38MP/E —$6.01$17.44
- LFVNLifevantage Corporation Common Stock (Delaware)$6.6▲ 2.33%Market cap $83.01MP/E 14.23$3.9$14.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics Inc. Common Stock | $92.29M | — | $1.49 | ▼ 3.57% | $1.07$6.18 |
| ONCY Oncolytics Biotech Inc. Common Stock | $92.50M | — | $0.8457 | ▼ 0.51% | $1.39$1.44 |
| FBIO Fortress Biotech Inc. Common Stock | $91.68M | 0.75 | $2.77 | ▼ 1.07% | $2.18$4.53 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $90.19M | — | $5.54 | ▲ 9.27% | $3.28$9.82 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $89.73M | — | $4.69 | ▲ 1.74% | $3.01$12.99 |
| ACET Adicet Bio Inc. Common Stock | $86.38M | — | $9.05 | ▲ 0.44% | $6.01$17.44 |
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.23 | $6.6 | ▲ 2.33% | $3.9$14.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →Acquired
487.6K
Disposed
0
- Nancy Miller-Rich · June 9, 2026 · Grant3.3K
- Nancy Miller-Rich · June 9, 2026 · Grant70.0K
- William D. Clark · June 9, 2026 · Grant2.3K
- DEPTULA-HICKS DARLENE M · June 9, 2026 · Grant84.6K
- Richard Douglas · June 9, 2026 · Grant2.3K
- Richard Douglas · June 9, 2026 · Grant19.9K
- Richard Douglas · June 9, 2026 · Grant70.0K
- William D. Clark · June 9, 2026 · Grant70.0K
- Walker Neal · June 9, 2026 · Grant3.3K
- Walker Neal · June 9, 2026 · Grant70.0K
- Bronstein Ben · June 9, 2026 · Grant5.0K
- Bronstein Ben · June 9, 2026 · Grant5.3K
- Bronstein Ben · June 9, 2026 · Grant70.0K
- Gary M. Phillips · June 9, 2026 · Grant5.0K
- Gary M. Phillips · June 9, 2026 · Grant6.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 36.91M
- Total value held
- $60.00M
- Institutional holders
- 119
Top holders this quarter
- Unknown5.48M
- Unknown3.76M
- Unknown2.83M
- Unknown2.36M
- Unknown2.15M
- Unknown1.50M
- Unknown1.40M
- Unknown1.25M
- Unknown1.25M
- Unknown1.14M
See the full, filterable feed with live charts on the MarketWall dashboard.